Steve E. Krognes Sells 3,339 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the transaction, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Denali Therapeutics Stock Up 0.3 %

Shares of DNLI opened at $21.25 on Thursday. Denali Therapeutics Inc. has a 52-week low of $14.56 and a 52-week high of $33.33. The firm has a market capitalization of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39. The firm has a 50-day moving average price of $24.34 and a 200 day moving average price of $24.88.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the company earned ($0.72) earnings per share. On average, equities analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on DNLI shares. HC Wainwright cut their target price on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. cut their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, William Blair initiated coverage on shares of Denali Therapeutics in a report on Friday, January 3rd. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.91.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNLI. JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after purchasing an additional 14,324 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after buying an additional 149,939 shares in the last quarter. Franklin Resources Inc. grew its position in Denali Therapeutics by 3.8% in the third quarter. Franklin Resources Inc. now owns 80,041 shares of the company’s stock worth $2,148,000 after buying an additional 2,901 shares during the last quarter. Barclays PLC increased its holdings in shares of Denali Therapeutics by 101.4% in the third quarter. Barclays PLC now owns 255,883 shares of the company’s stock valued at $7,454,000 after buying an additional 128,823 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics during the 3rd quarter valued at $1,894,000. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.